Skip to content

This US politician just made a really suspicious trade

This US politician just made a really suspicious trade
Elmaz Sabovic

As the stock market fluctuates, potentially wiping out recent gains, insider trading persists. Senator Tommy Tuberville is among those making moves ahead of the curve. 

Specifically, Tuberville recently invested an additional $80,000 in Humacyte (NASDAQ: HUMA) for a total of $225,000 in the previous year.

Humacyte is a company that uses implantable human tissue to treat combat wounds. This technology has shown promise in healing injuries from the conflict in Ukraine, and an innovative approach could potentially revolutionize the treatment of such wounds.

Senator Tuberville's purchase of HUMA stock. Source: Nancy Pelosi Stock Tracker
Senator Tuberville’s purchase of HUMA stock. Source: Nancy Pelosi Stock Tracker

Trades might not raise as many eyebrows if it weren’t for the fact that Tuberville is a member of the Armed Services Committee, which directly oversees grants and projects involving companies like Humacyte, adding to the suspicion surrounding Tuberville’s transactions.

HUMA stock is on a parabolic run

Since Tuberville’s investments in HUMA stock were revealed, the shares have soared by a remarkable 20% since April 16, with a hefty 15% boost in the latest trading session alone. 

Looking at the year-to-date chart, HUMA stock has increased by 24.22%, reaching a valuation of $3.59 as of the most recent close.

HUMA stock 24-hour price chart. Source: Google Finance
HUMA stock 24-hour price chart. Source: Google Finance

Humacyte offers its stock to fund further research

Humacyte announced a public offering of its common stock a month ago. The offering includes an option for underwriters to purchase up to 15% of the shares. 

The company intends to use the proceeds to advance its regenerative medicine pipeline, support the FDA’s review of its Biologics License Application for bioengineered human acellular vessels (HAVs), establish commercial infrastructure, and general corporate purposes. 

Humacyte’s HAVs, currently in late-stage clinical trials, are designed for various vascular applications, and two product candidates have received the FDA’s Regenerative Medicine Advanced Therapy designation.

If the FDA approves further applications from Humacyte, this could positively impact HUMA shares and drive their price higher.

Buy stocks now with eToro – trusted and advanced investment platform

Disclaimer: The content on this site should not be considered investment advice. Investing is speculative. When investing, your capital is at risk.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts